The information contained in this website has been developed by Arcutis Medical Affairs and is intended for US healthcare professionals (HCPs) only.
Explore a collection of congress presentations and published literature from Arcutis.
Roflumilast Cream (ARQ-151) 0.15% and 0.3% for Symptom Burden in Adults with Chronic Plaque Psoriasis in a Phase 2b Study
Roflumilast Cream (ARQ-151) for Itch Severity and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis in a Phase 2b Study
The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-Of-Concept Study
Roflumilast Cream for Plaque Psoriasis: Results From a Phase 1/2a Randomized, Controlled Study
ARQ-151, Roflumilast Cream, for Psoriasis in Phase 2a Study
ARQ-151, Roflumilast Cream, for Chronic Plaque Psoriasis in Phase 2b Study
Trial of Roflumilast Cream for Chronic Plaque Psoriasis
Your file will open automatically upon submission.
Fields marked with an asterisk (*) are required.
Arcutis Biotherapeutics, Inc. (“Arcutis”) understands that protecting your personal information is very important. We do not share any personally identifiable information you give us with third parties for their own marketing purposes.
I would like to receive occasional information from Arcutis about products, services, and opportunities that may be of interest to me and agree to allow Arcutis to use the information provided for this purpose. Examples include, but are not limited to, information or opportunities to participate in surveys or provide feedback, and information about clinical trials.
I can opt out at any time by clicking “Unsubscribe” at the bottom of any such communication, calling 805-418-5006, or by sending a letter to Arcutis Biotherapeutics, Inc., 3027 Townsgate Road, Suite 300, Westlake Village, CA 91361.
For additional details, please see Arcutis’ Privacy Policy.
By clicking Download below, I am agreeing to receive the requested information. I further acknowledge the Arcutis Privacy Policy and affirm that I am at least eighteen (18) years of age.
Δ
You are now leaving the Arcutis Medical Affairs website. Arcutis Biotherapeutics is not responsible for the content on these third-party websites.